{
    "clinical_study": {
        "@rank": "75705", 
        "acronym": "POC", 
        "arm_group": [
            {
                "arm_group_label": "Octreotide", 
                "arm_group_type": "Active Comparator", 
                "description": "Octreotide 100 mcg sc three times daily (t.i.d) for 4 weeks"
            }, 
            {
                "arm_group_label": "ITF2984 500 mcg", 
                "arm_group_type": "Experimental", 
                "description": "ITF2984 500 mcg sc twice a day (b.i.d) for 4 weeks"
            }, 
            {
                "arm_group_label": "ITF2984 1000 mcg", 
                "arm_group_type": "Experimental", 
                "description": "ITF2984 1000 mcg sc b.i.d for 4 weeks"
            }, 
            {
                "arm_group_label": "ITF2984 2000 mcg", 
                "arm_group_type": "Experimental", 
                "description": "ITF2984 2000 mcg sc b.i.d for 4 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate in acromegalic patients the effect of different\n      doses of ITF2984 on GH and IGF-1 concentrations and to investigate safety and tolerability\n      of three different doses of ITF2984."
        }, 
        "brief_title": "Phase II Study With ITF2984 in Acromegalic Patients", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Active Acromegaly", 
        "condition_browse": {
            "mesh_term": "Acromegaly"
        }, 
        "detailed_description": {
            "textblock": "The study will enroll patients with active acromegaly, de novo or partial responder to\n      previous treatment with somatostatin analogues. For patients who had previously received\n      medical therapy for acromegaly a washout periods before study entry of 3 months for\n      long-acting formulation of somatostatin analogs, 2 weeks for octreotide sc, 2 months for\n      pegvisomant and/or cabergoline must be foreseen.\n\n      Each patient will be randomized and wll remain in the study for about 6 months, and they\n      will attend a visit every two weeks.\n\n      The patients will be treated for 4 months in a total, in particular every month of treatment\n      will be followed by a washout period of 2 weeks.\n\n      At each month of treatment the patients will receive one of the four treatment as reported\n      below:\n\n      Octreotide 100 mcg sc three times daily (t.i.d) for 4 weeks, ITF2984 500 mcg sc twice a day\n      (b.i.d) for 4 weeks, ITF2984 1000 mcg sc b.i.d for 4 weeks, ITF2984 2000 mcg sc b.i.d for 4\n      weeks. Patients will be randomized using a 4 way crossover design to receive ITF2984 or\n      octreotide at each treatment month. Each patient will receive all of the four treatments\n      overseen in this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed written informed consent.\n\n          -  Patients with active acromegaly due to a pituitary adenoma. Active acromegaly should\n             be confirmed by 2h five point mean GH level higher than 5 mcg/liter, lack of\n             suppression of GH nadir to less than 1 mcg/liter after oral glucose tolerance test,\n             and elevated IGF-1 for age and sex-matched controls.\n\n          -  Patients aged between 18 to 80 years old inclusive.\n\n          -  Patients treated with previous surgery and/or medical therapy or previously untreated\n             (de novo). For patients who had previously received medical therapy for acromegaly a\n             washout periods before study entry of 3 months for long-acting formulation of\n             somatostatin analogs and 2 weeks for octreotide sc must be foreseen. Partial\n             responder means a significant decrease (>50%), without achievement of control of GH\n             and/or IGF-1 levels and/or >20 % tumor shrinkage after at least 6 months of SRL\n             therapy.\n\n          -  Patients with GH level and IGF-1 level for age and sex-matched controls out of range\n             at baseline.\n\n        Exclusion Criteria:\n\n          -  Patients undergone pituitary surgery within the prior 6 months.\n\n          -  Patients who have received pituitary radiotherapy (within last 10  years).\n\n          -  Patients with compression of the optic chiasm causing any visual field defect.\n\n          -  Patients who require a surgical intervention for relief of any sign or symptom\n             associated with tumor compression.\n\n          -  Patients with uncontrolled diabetes defined as having a fasting glucose > 150 mg/dL\n             (8.3 mmol/L) or HbA1c \u2265 8% (Patients can be rescreened after diabetes is brought\n             under adequate control).\n\n          -  Patients with significant cardiovascular morbidity within the three months preceding\n             enrollment.\n\n          -  Symptomatic cholelithiasis, gallstone or chronic liver disease.\n\n          -  Clinically significant GI, renal or hepatic disease (in the opinion of\n             investigator).\n\n          -  AST and/or ALT>2ULN.\n\n          -  Active HBV and/or active HCV infection.\n\n          -  Patients who have a history of alcohol or drug abuse in the six-month period prior to\n             the enrollment visit.\n\n          -  Known hypothyroidism or hypocortisolism not adequately treated with a stable dose of\n             thyroid or steroid hormone replacement therapy for at least the previous 3 months.\n\n          -  Known hypersensitivity to any of the study medications, or components thereof or a\n             history of drug or other allergy that in the opinion of the Investigator\n             contraindicates their participation.\n\n          -  Female patients who are pregnant or lactating, and female patient who are of\n             childbearing potential or male patient with female partners of childbearing potential\n             who do not accept the contraception requirements reported in the protocol\n\n          -  Patients who have participated in any clinical investigation with an Investigational\n             drug within 3 months before study entry.\n\n          -  Current or recent (< 2 months) therapy with pegvisomant or  cabergoline."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02111044", 
            "org_study_id": "DSC/13/2984/05"
        }, 
        "intervention": [
            {
                "arm_group_label": "Octreotide", 
                "intervention_name": "Octreotide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ITF2984 500 mcg", 
                "intervention_name": "ITF2984 500 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ITF2984 1000 mcg", 
                "intervention_name": "ITF2984 1000 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ITF2984 2000 mcg", 
                "intervention_name": "ITF2984 2000 mcg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Octreotide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "de novo patients or partial responder to previous treatment with somatostatin analogues", 
        "lastchanged_date": "April 8, 2014", 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Multicenter, Phase II Study to Investigate Efficacy and Safety of ITF2984 in Acromegalic Patients", 
        "overall_contact": {
            "email": "p.bettica@italfarmaco.com", 
            "last_name": "Paolo Bettica, MD", 
            "phone": "0039 02 6443 2584"
        }, 
        "overall_contact_backup": {
            "email": "s.manzoni@italfarmaco.com", 
            "last_name": "Sara Manzoni, MsB", 
            "phone": "0039 02 64432521"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Spanish Agency of Medicines", 
                "Romania: National Medicines Agency", 
                "Poland: Ministry of Health", 
                "Netherlands: Medical Ethics Review Committee (METC)", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines", 
                "Czech Republic: State Institute for Drug Control"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To investigate the effect of treatment on GH and IGF-1 concentrations", 
            "measure": "effect of treatment on GH and IGF-1", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02111044"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To investigate the biochemical response, defined as a reduction in (random) GH < 1.0 mcg/l and/or normalization of IGF-1.", 
                "measure": "reduction in (random) GH < 1.0 mcg/l and/or normalization of IGF-1", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "To investigate the biochemical response, defined as a reduction of GH to no more than 2.5 mcg/l and/or normalization of IGF-1.", 
                "measure": "reduction of GH to no more than 2.5 mcg/l and/or normalization of IGF-1", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "To evaluate variation of signs and symptoms of acromegaly at the end of each month of treatment in comparison with basal status.", 
                "measure": "signs and symptoms of acromegaly", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "To investigate the pharmacokinetic (PK) profile of ITF2984 and Octreotide", 
                "measure": "PK profile of ITF2984 and Octreotide", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "To compare the effects on GH and IGF1 circulating levels of different doses of ITF2984", 
                "measure": "dose-response effect of ITF2984 on GH and IGF1 circulating levels", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "To compare the effects on GH and IGF1 circulating levels of ITF2984 and Octreotide", 
                "measure": "effects of ITF2984 vs Octreotide on GH and IGF1 circulating levels", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Italfarmaco", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Italfarmaco", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}